Influenza management guide 2009-2010.

摘要

The extensive spread of 2009 pandemic influenza A H1N1, also referred to as novel H1N1 2009 or swine flu, and the arrival of seasonal influenza present critical public health and clinical challenges. Key steps for the primary care physician are prevention efforts (e.g., vaccinating and educating patients about hygiene) and treatment of affected patients who are at high risk of influenza-related complications. The goal of medication therapy is not curative but rather to prevent severe illness and reduce the incidence of influenza-related complications for patients at highest risk. The 2009 H1N1 influenza virus has thus far been sensitive to the neuraminidase inhibitors oselta-mivir (Tamiflu) and zanamivir (Relenza), with only rare oseltamivir resistance; however, it has complete resistance to adamantanes (rimantadine [Flumadine] and amantadine [Symmetrel]). Seasonal influenza, conversely, has a reverse sensitivity profile that is almost entirely resistant to oseltamivir and sensitive to adamantanes.